During a live event, Alfred L. Garfall, MD, discussed the dose adjustments and supportive care for toxicities seen with ...

Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated ...

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual ...

An expert emphasizes that treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) are highly ...